Assays, antibodies, immunogens and compositions related to 5-FU
The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.
1. An antibody or fragment thereof that binds to 5-fluorouracil (5-FU), wherein the antibody or fragment thereof comprises the heavy chain amino acid sequence of amino acids 20-477 of SEQ ID NO:2, and the light chain amino acid sequence of amino acids 21-234 of SEQ ID NO:6.
2. A method of detecting 5-fluorouracil (5-FU) in a sample, comprising:
(1) combining in a solution at least said sample with
(a) a first binding molecule, wherein the first binding molecule comprises an antibody or fragment thereof,
wherein the antibody or fragment thereof comprises the heavy chain amino acid sequence of amino acids 20-477 of SEQ ID NO:2, and the light chain amino acid sequence of amino acids 21-234 of SEQ ID NO:6, and is capable of binding 5-FU; and
(b) a detector molecule comprising a detection label,
wherein the detection label is selected from the group consisting of an electrochemiluminescence label, an enzyme label, a fluorophore, a latex particle, a magnetic particle, a radioactive element, a phosphorescent dye, a dye crystalite, a gold particle, a silver colloidal particle, a selenium colloidal particle, a ruthenium metal chelate, an osmium metal chelate a coenzyme, an electro active group, an oligonucleotide and a stable radical,
wherein the first binding molecule can bind the detector molecule, and
wherein 5-FU, if present in the sample, competitively inhibits the binding of the first binding molecule to the detector molecule; and
(2) detecting the presence of 5-FU in the sample by detecting a signal or lack thereof from the detection label of the detector molecule after binding to the first binding molecule, wherein the presence of 5-FU is inversely proportional to the binding of the first binding molecule to the detector molecule.
3. The method of claim 2 , wherein the sample is a serum sample from a mammal.
4. The method of claim 2 , wherein the sample is diluted prior to combining with the first binding molecule.
5. The method of claim 2 , wherein the sample is not diluted prior to combining with the first binding molecule.
6. The method of any one of claims 2 , 3 , 4 and 5 , wherein the sample is blood plasma.
7. The method of claim 2 , wherein at least the first binding molecule or the detector molecule is from a lyophilized composition that is rehydrated with the sample.
8. The method of claim 2 , wherein the first binding molecule is from a lyophilized composition.
9. The method of claim 2 , wherein the detector molecule is from a lyophilized composition.
10. The method of claim 2 , wherein the first binding molecule and the detector molecule are lyophilized in separate compositions.
11. The method of claim 10 , wherein the separate lyophilized compositions are rehydrated with the sample.
12. The method of claim 2 , wherein the method has a lower detection limit of <5.0 ng/mL.
13. The method of claim 2 , wherein the method has a dynamic range of 10-30,000 ng/mL.
14. The method of claim 2 , wherein the method is completed in less than 15 minutes.
15. The method of claim 2 , wherein the sample is from a patient and the method further comprises adjusting a patient's dose of 5-FU based on the amount of 5-FU detected in the sample.
16. The method of claim 2 , wherein the solution comprises GPRP-NH 2 (SEQ ID NO:1).
17. The method of claim 2 , wherein the first binding molecule is bound to a surface.
18. The method of claim 2 , wherein after the solution is incubated for a period of time, the first binding molecule is then bound to a surface.
19. The method of claim 18 , wherein the first binding molecule and the surface each are comprised of a corresponding member of a binding pair.
20. The method of claim 19 , wherein the binding pair is streptavidin and biotin.
21. The method of claim 20 , wherein the first binding molecule comprises biotin.
22. The method of any one of claims 17 - 21 , wherein the surface is a bead.
23. The method of claim 22 , wherein the bead is a paramagnetic bead.
24. The method of claim 3 , wherein the mammal is a human.
25. The method of claim 2 , wherein the first binding molecule is produced by immunizing an animal with the compound of the formula with the compound of the formula:
wherein R is the keyhole limpet hemocyanin (KLH).